ArticlePloS one2026
Cost-effectiveness of percutaneous patent foramen ovale closure versus medical therapy for cryptogenic stroke prevention: A Chinese healthcare perspective.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatent foramen ovale occurs in approximately 25% of cryptogenic stroke patients, with paradoxical embolization representing a key pathophysiological mechanism. While recent trials have established the clinical efficacy of percutaneous PFO closure in reducing recurrent stroke risk, comprehensive economic evaluation within the Chinese healthcare framework remains limited. This study assessed the cost-effectiveness of PFO closure compared with medical therapy alone in Chinese patients with cryptogenic stroke.
methodsA Markov cohort model was constructed with four health states (stable, post-minor recurrent stroke, post-moderate-to-severe recurrent stroke, death) using 3-month cycles over a 30-year horizon. The analysis adopted a Chinese healthcare payer perspective, incorporating transition probabilities derived primarily from the RESPECT trial extended follow-up data and Chinese-specific cost data from multi-center hospital surveys. Primary outcome was the incremental cost-effectiveness ratio (ICER) evaluated against China's willingness-to-pay threshold of $37,654 per quality-adjusted life year (QALY). Extensive sensitivity analyses examined parameter uncertainty and model robustness.
resultsPFO closure demonstrated economic dominance over medical therapy, yielding 1.41 additional QALYs (13.42 vs 12.01) while reducing lifetime costs by $4,045 per patient ($8,847 vs $12,892). The resulting negative ICER of -$2,868 per QALY indicated superior outcomes at lower cost. Probabilistic sensitivity analysis revealed 94.2% probability of cost-effectiveness at the Chinese threshold. One-way sensitivity analyses consistently showed negative ICERs across all parameter ranges, with time horizon and psychological comorbidity costs exerting the greatest influence on results.
conclusionsIn the Chinese healthcare context, PFO closure represents a dominant economic strategy for cryptogenic stroke patients, providing both clinical benefits and cost savings. These findings support broader implementation of PFO closure programs and inform evidence-based resource allocation decisions for stroke prevention services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.